<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00579527</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00011583</org_study_id>
    <secondary_id>2R01AI047040-11A2</secondary_id>
    <secondary_id>R56 Bridge R01AI4704011A1</secondary_id>
    <secondary_id>5K12HD043494-09</secondary_id>
    <secondary_id>R01AI047040</secondary_id>
    <secondary_id>R01AI054843</secondary_id>
    <secondary_id>950</secondary_id>
    <nct_id>NCT00579527</nct_id>
  </id_info>
  <brief_title>Phase I/II Thymus Transplantation With Immunosuppression #950</brief_title>
  <acronym>#950</acronym>
  <official_title>Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M. Louise Markert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Enzyvant Therapeutics GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously
      described as transplantation) with tailored immunosuppression based on the recipient's
      pre-implantation T cell population is a safe and effective treatment for complete DiGeorge
      anomaly. This study will also evaluate whether cultured thymus tissue implantation and
      parathyroid transplantation with immunosuppression is a safe and effective treatment for
      complete DiGeorge anomaly and hypoparathyroidism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complete DiGeorge anomaly is a congenital disorder characterized by athymia. Without
      successful treatment, children remain immunodeficient and usually die by age 2 years. In
      infants with complete DiGeorge anomaly and no T cells, cultured thymus tissue implantation
      (CTTI) without immunosuppression resulted in diverse T cell development and good T cell
      function. Some infants with no thymus have some T cells that presumably developed
      extrathymically; these T cells can reject a thymus graft.

      The purpose of this study is to tailor immunosuppression use for complete DiGeorge anomaly
      subjects who have some T cells and different T cell function levels. This protocol includes
      tailored immunosuppression regimens to allow subjects with different T cell function levels
      to be suppressed adequately.

      Patients with complete DiGeorge often have hypoparathyroidism, a life threatening condition.
      Successful CTTI does not result in improvement of the hypoparathyroidism. The patients must
      go to the clinic for frequent calcium levels and to the hospital for calcium infusions. These
      infants are at risk for seizures from low calcium. This study had a parental parathyroid
      transplant arm for subjects with hypoparathyroidism who require calcium replacement.

      Whether or not a subject was enrolled in the parathyroid arm, the immunosuppression regimen
      the subject received was dependent on the immune findings as stated in the clinical protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2005</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival at 1 Year Post-CTTI</measure>
    <time_frame>1 year post-CTTI</time_frame>
    <description>Survival at 1 year post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival at 2 Years Post-CTTI</measure>
    <time_frame>2 years post-CTTI</time_frame>
    <description>Survival at 2 years post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution Efficacy - Total CD3 T Cells</measure>
    <time_frame>1 year post-CTTI</time_frame>
    <description>The development of total CD3 T cells at one year as measured using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution Efficacy - Total CD4 T Cells</measure>
    <time_frame>1 year post-CTTI</time_frame>
    <description>The development of total CD4 T cells at one year as measured using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution Efficacy - Total CD8 T Cells</measure>
    <time_frame>1 year post-CTTI</time_frame>
    <description>The development of total CD8 T cells at one year as measured using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution Efficacy - Naive CD4 T Cells</measure>
    <time_frame>1 year post-CTTI</time_frame>
    <description>The development of total naive CD4 T cells at one year as measured using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution Efficacy - Naive CD8 T Cells</measure>
    <time_frame>1 year post-CTTI</time_frame>
    <description>The development of total naive CD8 T cells at one year as measured using flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution Efficacy - Response to Mitogens</measure>
    <time_frame>1 year post-CTTI</time_frame>
    <description>Measurement of the T cell proliferative response to the mitogen phytohemagglutin (PHA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thymus Allograft Biopsy</measure>
    <time_frame>2 to 3 months post-CTTI</time_frame>
    <description>Evidence, on biopsy of the thymus tissue implanted in muscle, that shows the development of new T cells.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>DiGeorge Anomaly</condition>
  <condition>Complete DiGeorge Anomaly</condition>
  <condition>Complete Atypical DiGeorge Anomaly</condition>
  <condition>Complete DiGeorge Syndrome</condition>
  <condition>Complete Atypical DiGeorge Syndrome</condition>
  <arm_group>
    <arm_group_label>Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with complete DiGeorge Anomaly (cDGA) undergo cultured thymus tissue implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTTI with Parathyroid Transplantation w/immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with complete DiGeorge Anomaly (cDGA) undergoes cultured thymus tissue thymus implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function. If the patient has hypoparathyroidism, and is eligible, the patient may also receive a parathyroid transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cultured Thymus Tissue for Implantation (CTTI)</intervention_name>
    <description>Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.</description>
    <arm_group_label>Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression</arm_group_label>
    <other_name>Thymus Tissue Transplant</other_name>
    <other_name>CTTI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation</intervention_name>
    <description>For subjects w/ hypoparathyroidism, the subject may receive CTTI and parathyroid transplant. For parathyroid transplant, parental parathyroid donors are screened. Parathyroid is harvested from the parent who shares the most Human Leukocyte Antigens (HLA) alleles with the thymus donor. Parathyroid gland is minced and placed in quadriceps muscle; there is no dose. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely. Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of CTTI and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.</description>
    <arm_group_label>CTTI with Parathyroid Transplantation w/immunosuppression</arm_group_label>
    <other_name>Thymus and Parathyroid Transplant</other_name>
    <other_name>CTTI and Parathyroid Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>Birth mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab may be done.</description>
    <arm_group_label>CTTI with Parathyroid Transplantation w/immunosuppression</arm_group_label>
    <arm_group_label>Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression</arm_group_label>
    <other_name>Venipuncture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit anti-thymocyte globulin</intervention_name>
    <description>Three doses of 2 mg/kg IV (through a central venous catheter) prior to CTTI. Each dose of Rabbit anti-thymocyte globulin (RATGAM) is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to CTTI or CTTI and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.</description>
    <arm_group_label>CTTI with Parathyroid Transplantation w/immunosuppression</arm_group_label>
    <arm_group_label>Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression</arm_group_label>
    <other_name>RATGAM</other_name>
    <other_name>thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>In addition to RATGAM, subjects with typical cDGA with PHA responses &gt;50,000 cpm, or atypical cDGA with PHA response &lt;75,000cpm (when not on immunosuppression) or &lt;40,000 cpm to PHA while on immunosuppression, are started on cyclosporine (Csa) as soon as cDGA is diagnosed. Csa is continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately.
Csa may be given every 8 to 12 hours enterally or IV before and after CTTI. The Csa dose is dependent on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol.</description>
    <arm_group_label>CTTI with Parathyroid Transplantation w/immunosuppression</arm_group_label>
    <arm_group_label>Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression</arm_group_label>
    <other_name>Csa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>If unable to tolerate cyclosporine, then tacrolimus is given. Tacrolimus may be given every 8 to 12 hours enterally or IV before and after the CTTI transplant. Tacrolimus dose is dependent on the T cell numbers and the target tacrolimus trough levels. Tacrolimus is weaned as per protocol.</description>
    <arm_group_label>CTTI with Parathyroid Transplantation w/immunosuppression</arm_group_label>
    <arm_group_label>Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression</arm_group_label>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone or Prednisolone</intervention_name>
    <description>Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells &gt;4,000cumm. Steroids are weaned as per protocol.</description>
    <arm_group_label>CTTI with Parathyroid Transplantation w/immunosuppression</arm_group_label>
    <arm_group_label>Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression</arm_group_label>
    <other_name>Steroids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclizumab</intervention_name>
    <description>In addition, subjects with Atypical DiGeorge with PHA responses &gt;75,000cpm while on no immunosuppression or PHA responses &gt;40,000cpm while on immunosuppression, Daclizumab 1 mg/kg single dose IV may be given depending on T cell counts. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before CTTI. If Daclizumab is not given before CTTI, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after CTTI.</description>
    <arm_group_label>Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression</arm_group_label>
    <other_name>Zenapax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>In addition, subjects with Atypical DiGeorge with PHA responses &gt;75,000cpm while on no immunosuppression or PHA responses &gt;40,000cpm while on immunosuppression, Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV or enterally may be given depending on T cell counts. Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after CTTI. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after CTTI or continued for up to six months after CTTI.</description>
    <arm_group_label>Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Thymus Transplantation Inclusion:

          -  Must have 1 of following: 22q11 or 10p13 hemizygosity; hypocalcemia requiring
             replacement; congenital heart defect; CHARGE association or CHD7 mutation; or abnormal
             ears plus mother w/diabetes (type I, type II, gestational).

          -  &lt;50 CD3+ T cells/cumm or &lt;50 CD3+ T cells/cumm that are CD62L+ CD45RA+ (cluster of
             differentiation 45RA) (naïve phenotype), or &lt;5% of CD3+ count being CD62L+ CD45RA+

        Atypical DiGeorge:

          -  Must have, or have had, a rash. If rash present, rash biopsy must show T cells in
             skin. If rash &amp; adenopathy resolved, must have &gt;50/cumm T cells &amp; naive T cell must be
             &lt;50/cumm or &lt;5% of T cells.

        Typical DiGeorge:

          -  CD3+ CD45RA+ CD62L+ T cells &lt;50/mm3 or &lt;5% of total T cells

        Parathyroid Transplantation Additional Inclusion:

          -  2 studies in recipient which PTH&lt;5 pg/ml when ionized calcium &lt;1.1 mmol/L. Can be done
             anytime pre-tx; 1 must be done while at Duke Hospital.

          -  Parent(s) willing &amp; eligible to be donors

        Thymus Transplantation Exclusion:

          -  Heart surgery &lt;4 wks pre-tx

          -  Heart surgery anticipated w/in 3 months after proposed tx

          -  Rejection by surgeon or anesthesiologist as surgical candidate

          -  Lack of sufficient muscle tissue to accept transplant of 4 grams/m2 BSA

          -  HIV infection

          -  Prior attempts at immune reconstitution, such as bone marrow tx or previous thymus tx

          -  CMV(&gt;500 copies/ml blood by PCR on 2 tests)

          -  Ventilator dependence

        Parathyroid Donor Inclusion:

          -  &gt;18 years of age

          -  Serum calcium in normal range

          -  Normal PTH function

          -  HLA typing consistent with parentage

          -  Not on anticoagulation or can come off

          -  Parent chosen will share HLA-DR allele with thymus donor that was not inherited by the
             recipient. If no HLA matching at all, then either parent is acceptable if the parent
             meets other criteria.

        Parathyroid Donor Exclusion:

          -  &lt;18 years old

          -  Hypoparathyroidism-low PTH in presence of low serum calcium &amp; high serum phosphate

          -  Hyperparathyroidism(or history)-elevated PTH in presence of high serum calcium and low
             serum phosphate.

          -  History of cancer

          -  Donor only living involved parent/guardian of recipient

          -  Evidence of HIV-1, HIV-2, HTLV-1, HTLV-2, syphilis, hepatitis B, hepatitis C, West
             Nile virus, or Chagas disease

          -  Creutzfeldt Jakob disease (CJD)

          -  Elevated liver function studies: AST, ALT, alkaline phosphatase &gt;3x upper normal limit

          -  Receipt of xenograft or risk factors for SARS, CJD and/or smallpox exposure. {If CJD
             risk factors but not active disease, parent may give permission for parathyroid use.}

          -  Urine CMV positive

          -  Positive CMV IgM

          -  Positive IgM anti-EBV VCA

          -  On blood thinners and cannot stop for parathyroid donation

          -  Elevated PT or PTT (&gt;ULN)

          -  Platelets&lt;100,000

          -  Positive Toxoplasma IgM

          -  Donor will receive a history and physical; may be excluded based on PI's medical
             judgment.

          -  Hemoglobin &lt;9g/dl

          -  Infectious head or neck lesion

          -  Goiter on ultrasound

          -  Abnormal fiberoptic laryngoscopy of vocal cords

          -  HLA inconsistent with parentage

          -  Pregnancy

          -  Positive HSV IgG isn't exclusion; post-tx prophylaxis needed for recipient if donor is
             HSV IgG+.

          -  Positive VZV IgG isn't exclusion; post-tx prophylaxis needed if donor is VZV IgG+.

          -  Medical concern of independent otolaryngologist.

          -  Concern by medical psychologist/social worker that potential donor isn't competent or
             does not understand risks.

          -  Questionnaire responses can lead to exclusion.

        Mother of DiGeorge Inclusion:

        • Provides consent to use blood/buccal sample. No exclusions except unwillingness to
        consent; or, provide blood/buccal sample.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Louise Markert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center, Pediatrics, Allergy &amp; Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Markert ML, Devlin BH, Alexieff MJ, Li J, McCarthy EA, Gupton SE, Chinn IK, Hale LP, Kepler TB, He M, Sarzotti M, Skinner MA, Rice HE, Hoehner JC. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood. 2007 May 15;109(10):4539-47. Epub 2007 Feb 6.</citation>
    <PMID>17284531</PMID>
  </reference>
  <reference>
    <citation>Markert ML, Alexieff MJ, Li J, Sarzotti M, Ozaki DA, Devlin BH, Sedlak DA, Sempowski GD, Hale LP, Rice HE, Mahaffey SM, Skinner MA. Postnatal thymus transplantation with immunosuppression as treatment for DiGeorge syndrome. Blood. 2004 Oct 15;104(8):2574-81. Epub 2004 Apr 20.</citation>
    <PMID>15100156</PMID>
  </reference>
  <reference>
    <citation>Markert ML and Devlin BH. Thymic reconstitution (in Rich RR, Shearer WT, Fleischer T, Schroeder HW, Weyand CM, Frew A, eds., Clinical Immunology 3rd edn., Elsevier, Edinburgh) p 1253-1262, 2008.</citation>
  </reference>
  <reference>
    <citation>Selim MA, Markert ML, Burchette JL, Herman CM, Turner JW. The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study. J Cutan Pathol. 2008 Apr;35(4):380-5. doi: 10.1111/j.1600-0560.2007.00816.x.</citation>
    <PMID>18333898</PMID>
  </reference>
  <reference>
    <citation>Chinn IK, Devlin BH, Li YJ, Markert ML. Long-term tolerance to allogeneic thymus transplants in complete DiGeorge anomaly. Clin Immunol. 2008 Mar;126(3):277-81. Epub 2007 Dec 26.</citation>
    <PMID>18155964</PMID>
  </reference>
  <reference>
    <citation>Markert ML, Alexieff MJ, Li J, Sarzotti M, Ozaki DA, Devlin BH, Sempowski GD, Rhein ME, Szabolcs P, Hale LP, Buckley RH, Coyne KE, Rice HE, Mahaffey SM, Skinner MA. Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases. J Allergy Clin Immunol. 2004 Apr;113(4):734-41.</citation>
    <PMID>15100681</PMID>
  </reference>
  <reference>
    <citation>Markert ML, Sarzotti M, Ozaki DA, Sempowski GD, Rhein ME, Hale LP, Le Deist F, Alexieff MJ, Li J, Hauser ER, Haynes BF, Rice HE, Skinner MA, Mahaffey SM, Jaggers J, Stein LD, Mill MR. Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients. Blood. 2003 Aug 1;102(3):1121-30. Epub 2003 Apr 17.</citation>
    <PMID>12702512</PMID>
  </reference>
  <reference>
    <citation>Li B, Li J, Devlin BH, Markert ML. Thymic microenvironment reconstitution after postnatal human thymus transplantation. Clin Immunol. 2011 Sep;140(3):244-59. doi: 10.1016/j.clim.2011.04.004. Epub 2011 Apr 16.</citation>
    <PMID>21565561</PMID>
  </reference>
  <reference>
    <citation>Chinn IK, Olson JA, Skinner MA, McCarthy EA, Gupton SE, Chen DF, Bonilla FA, Roberts RL, Kanariou MG, Devlin BH, Markert ML. Mechanisms of tolerance to parental parathyroid tissue when combined with human allogeneic thymus transplantation. J Allergy Clin Immunol. 2010 Oct;126(4):814-820.e8. doi: 10.1016/j.jaci.2010.07.016. Epub 2010 Sep 15.</citation>
    <PMID>20832849</PMID>
  </reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, McCarthy EA. Thymus transplantation. Clin Immunol. 2010 May;135(2):236-46. doi: 10.1016/j.clim.2010.02.007. Epub 2010 Mar 16. Review.</citation>
    <PMID>20236866</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Li J, Devlin BH, Hoehner JC, Rice HE, Skinner MA, Li YJ, Hale LP. Use of allograft biopsies to assess thymopoiesis after thymus transplantation. J Immunol. 2008 May 1;180(9):6354-64.</citation>
    <PMID>18424759</PMID>
  </results_reference>
  <results_reference>
    <citation>Hudson LL, Louise Markert M, Devlin BH, Haynes BF, Sempowski GD. Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection. Semin Immunol. 2007 Oct;19(5):297-309. Epub 2007 Nov 26. Review.</citation>
    <PMID>18035553</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, Chinn IK, McCarthy EA, Li YJ. Factors affecting success of thymus transplantation for complete DiGeorge anomaly. Am J Transplant. 2008 Aug;8(8):1729-36. doi: 10.1111/j.1600-6143.2008.02301.x. Epub 2008 Jun 28.</citation>
    <PMID>18557726</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, McCarthy EA, Chinn IK, Hale LP. Thymus Transplantation in Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features. Eds Lavinin C, Moran CA, Morandi U, Schoenhuber R. Springer-Verlag Italia, Milan, 2008, pp 255-267.</citation>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, Chinn IK, McCarthy EA. Thymus transplantation in complete DiGeorge anomaly. Immunol Res. 2009;44(1-3):61-70. doi: 10.1007/s12026-008-8082-5.</citation>
    <PMID>19066739</PMID>
  </results_reference>
  <results_reference>
    <citation>Chinn IK, Milner JD, Scheinberg P, Douek DC, Markert ML. Thymus transplantation restores the repertoires of forkhead box protein 3 (FoxP3)+ and FoxP3- T cells in complete DiGeorge anomaly. Clin Exp Immunol. 2013 Jul;173(1):140-9. doi: 10.1111/cei.12088.</citation>
    <PMID>23607606</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <results_first_submitted>December 27, 2019</results_first_submitted>
  <results_first_submitted_qc>February 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2020</results_first_posted>
  <disposition_first_submitted>December 10, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>December 10, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 12, 2016</disposition_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>M. Louise Markert</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>DiGeorge Anomaly</keyword>
  <keyword>Thymus Transplantation</keyword>
  <keyword>DiGeorge Syndrome</keyword>
  <keyword>Athymia</keyword>
  <keyword>Parathyroid Transplantation</keyword>
  <keyword>Hypocalcemia</keyword>
  <keyword>Hypoparathyroidism</keyword>
  <keyword>Low T cell numbers</keyword>
  <keyword>Immunoreconstitution</keyword>
  <keyword>Immunodeficiency</keyword>
  <keyword>Complete DiGeorge Anomaly</keyword>
  <keyword>Complete Atypical DiGeorge Anomaly</keyword>
  <keyword>Complete DiGeorge Syndrome</keyword>
  <keyword>Complete Atypical DiGeorge Syndrome</keyword>
  <keyword>Cultured Thymus Tissue Implantation (CTTI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>DiGeorge Syndrome</mesh_term>
    <mesh_term>Craniosynostoses</mesh_term>
    <mesh_term>Marfan Syndrome</mesh_term>
    <mesh_term>Arachnodactyly</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Daclizumab</mesh_term>
    <mesh_term>Parathyroid Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The goal of this study is survival of subjects after cultured thymus tissue implantation (CTTI) regardless of the immunosuppressive regimen or of parathyroid co-transplantation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cultured Thymus Tissue Implantation w/ Immunosuppression</title>
          <description>Participants enrolled in cultured thymus tissue implantation (CTTI) with immunosuppression were given immunosuppression based on results of flow cytometry without consideration of whether a parathyroid transplant would be given.
No participants were enrolled into Arm 2. No subjects received a parathyroid transplant.
No specific dose of cultured thymus tissue was assigned. The dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the participant.
There was one administration of cultured thymus tissue. The dosage form was cultured thymus tissue.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
      <group_list>
        <group group_id="B1">
          <title>Cultured Thymus Tissue Implantation With Immunosuppression</title>
          <description>Participants enrolled into cultured thymus tissue for implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject’s pre-implantation T cell number and function.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="248" spread="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than One Race (Caucasian/Asian)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival at 1 Year Post-CTTI</title>
        <description>Survival at 1 year post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.</description>
        <time_frame>1 year post-CTTI</time_frame>
        <population>The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Cultured Thymus Tissue With Immunosuppression</title>
            <description>Participants enrolled into cultured thymus tissue for Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject’s pre-implantation T cell numbers and function.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival at 1 Year Post-CTTI</title>
          <description>Survival at 1 year post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.</description>
          <population>The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
          <units>% of participants who survive to 1 year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="40.6" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival at 2 Years Post-CTTI</title>
        <description>Survival at 2 years post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.</description>
        <time_frame>2 years post-CTTI</time_frame>
        <population>The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Cultured Thymus Tissue Implantation With Immunosuppression</title>
            <description>Participants enrolled into Cultured Thymus Tissue Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject’s pre-implantation T cell numbers and function.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival at 2 Years Post-CTTI</title>
          <description>Survival at 2 years post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.</description>
          <population>The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
          <units>% of participants who survive to 2 years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="40.6" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution Efficacy - Total CD3 T Cells</title>
        <description>The development of total CD3 T cells at one year as measured using flow cytometry</description>
        <time_frame>1 year post-CTTI</time_frame>
        <population>Data were only included for the 1 year time point if a CD3 T cell count was performed in relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Cultured Thymus Tissue Implantation With Immunosuppression</title>
            <description>Participants enrolled into Cultured Thymus Tissue Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject’s pre-implantation T cell numbers and function.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution Efficacy - Total CD3 T Cells</title>
          <description>The development of total CD3 T cells at one year as measured using flow cytometry</description>
          <population>Data were only included for the 1 year time point if a CD3 T cell count was performed in relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="726" lower_limit="345" upper_limit="1866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution Efficacy - Total CD4 T Cells</title>
        <description>The development of total CD4 T cells at one year as measured using flow cytometry</description>
        <time_frame>1 year post-CTTI</time_frame>
        <population>Data were only included for the 1 year time point if a CD4 T cell count was performed in relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Cultured Thymus Tissue Implantation With Immunosuppression</title>
            <description>Participants enrolled into Cultured Thymus Tissue Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject’s pre-implantation T cell numbers and function.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution Efficacy - Total CD4 T Cells</title>
          <description>The development of total CD4 T cells at one year as measured using flow cytometry</description>
          <population>Data were only included for the 1 year time point if a CD4 T cell count was performed in relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="593" lower_limit="230" upper_limit="1780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution Efficacy - Total CD8 T Cells</title>
        <description>The development of total CD8 T cells at one year as measured using flow cytometry</description>
        <time_frame>1 year post-CTTI</time_frame>
        <population>Data were only included for the 1 year time point if a CD8 T cell count was performed in relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Cultured Thymus Tissue Implantation With Immunosuppression</title>
            <description>Participants enrolled into Cultured Thymus Tissue Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject’s pre-implantation T cell numbers and function.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution Efficacy - Total CD8 T Cells</title>
          <description>The development of total CD8 T cells at one year as measured using flow cytometry</description>
          <population>Data were only included for the 1 year time point if a CD8 T cell count was performed in relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145" lower_limit="22" upper_limit="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution Efficacy - Naive CD4 T Cells</title>
        <description>The development of total naive CD4 T cells at one year as measured using flow cytometry</description>
        <time_frame>1 year post-CTTI</time_frame>
        <population>Data were only included for the 1 year time point if a T cell count was performed in relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Cultured Thymus Tissue Implantation With Immunosuppression</title>
            <description>Participants enrolled into Cultured Thymus Tissue Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject’s pre-implantation T cell numbers and function.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution Efficacy - Naive CD4 T Cells</title>
          <description>The development of total naive CD4 T cells at one year as measured using flow cytometry</description>
          <population>Data were only included for the 1 year time point if a T cell count was performed in relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156" lower_limit="23" upper_limit="751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution Efficacy - Naive CD8 T Cells</title>
        <description>The development of total naive CD8 T cells at one year as measured using flow cytometry</description>
        <time_frame>1 year post-CTTI</time_frame>
        <population>Data were only included for the 1 year time point if a T cell count was performed in the relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Cultured Thymus Tissue Implantation With Immunosuppression</title>
            <description>Participants enrolled into Cultured Thymus Tissue Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject’s pre-implantation T cell numbers and function.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution Efficacy - Naive CD8 T Cells</title>
          <description>The development of total naive CD8 T cells at one year as measured using flow cytometry</description>
          <population>Data were only included for the 1 year time point if a T cell count was performed in the relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="4" upper_limit="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution Efficacy - Response to Mitogens</title>
        <description>Measurement of the T cell proliferative response to the mitogen phytohemagglutin (PHA).</description>
        <time_frame>1 year post-CTTI</time_frame>
        <population>Data were only included for the 1 year time point if a testing was performed in the relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Cultured Thymus Tissue Implantation With Immunosuppression</title>
            <description>Participants enrolled into Cultured Thymus Tissue Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject’s pre-implantation T cell numbers and function.</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution Efficacy - Response to Mitogens</title>
          <description>Measurement of the T cell proliferative response to the mitogen phytohemagglutin (PHA).</description>
          <population>Data were only included for the 1 year time point if a testing was performed in the relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
          <units>counts per minute (cpm)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139189" lower_limit="13726" upper_limit="202132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thymus Allograft Biopsy</title>
        <description>Evidence, on biopsy of the thymus tissue implanted in muscle, that shows the development of new T cells.</description>
        <time_frame>2 to 3 months post-CTTI</time_frame>
        <population>Data were only included if the participant had a biopsy of the thymus tissue implanted. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Cultured Thymus Tissue Implantation With Immunosuppression</title>
            <description>Participants enrolled into Cultured Thymus Tissue Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject’s pre-implantation T cell numbers and function.</description>
          </group>
        </group_list>
        <measure>
          <title>Thymus Allograft Biopsy</title>
          <description>Evidence, on biopsy of the thymus tissue implanted in muscle, that shows the development of new T cells.</description>
          <population>Data were only included if the participant had a biopsy of the thymus tissue implanted. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Evidence of thymopoiesis</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Evidence of rejection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Inconclusive for thymopoiesis</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years post-CTTI</time_frame>
      <desc>Participants enrolled into Cultured Thymus Tissue for Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject’s pre-implantation T cell numbers and function. All adverse events are reported below.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cultured Thymus Tissue Implantation With Immunosuppression</title>
          <description>Participants enrolled into Cultured Thymus Tissue Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject’s pre-implantation T cell numbers and function. All adverse events were combined for this analysis regardless of the immunosuppression used.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Systemic immune activation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="34" subjects_affected="11" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cystitis escherichia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cystitis klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pneumonia moraxella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Feeding intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemic seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Granuloma skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Eye infection bacterial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cystitis klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastroenteritis adenovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pneumonia moraxella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Stoma site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Stoma site hypergranulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Allergic transfusion reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood chloride decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood immunoglobulin E increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Red blood cell morphology abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Disaccharidase deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Feeding intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Metabolic alkalosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nephrocalcinosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral breast buds</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lymphorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>M. Louise Markert, MD, PhD Professor of Pediatrics and Immunology</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-6263</phone>
      <email>marke001@mc.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

